key: cord-0943397-xlqi479u
authors: Levengood, Timothy W.; Aronsohn, Andrew; Chua, Kao-Ping; Conti, Rena
title: Dispensing of HIV and HCV Antivirals During COVID-19: An Interrupted Time Series Analysis of U.S. National Data
date: 2022-05-20
journal: Am J Prev Med
DOI: 10.1016/j.amepre.2022.04.024
sha: d3531042d91e720504b54c3d16b0fbd03f66a0f2
doc_id: 943397
cord_uid: xlqi479u

Introduction Little is known about potential changes in dispensation of life-saving hepatitis C (HCV) and HIV antivirals following the initial U.S. outbreak of COVID-19. The objective of this study was to describe the immediate and 1-year impacts of the U.S. outbreak of COVID-19 on monthly dispensing of HIV and HCV antivirals, specifically direct-acting antivirals (DAAs) to treat HCV, antiretroviral therapy (ART) to treat HIV, and pre-exposure prophylaxis (PrEP) to prevent HIV. Methods Authors used interrupted time series analysis, examining IQVIA National Prescription Audit® (includes 92% of U.S. retail pharmacies and 70% of U.S. mail-order and long-term care pharmacies) for changes in monthly dispensed prescriptions, 2 years before and 1 year after the initial U.S. COVID-19 outbreak. Fitted linear segmented regression models were used to assess immediate level and slope changes, excluding data from April 2020 as a washout period. Authors stratified analyses by new/refill, age group, payer type, and delivery channel. Results Following initial outbreak, DAA prescription dispensing declined almost one-third. The COVID-19 outbreak was associated with an immediate level decrease in total DAA prescriptions, followed by a slope increase in monthly dispensing. However, by April 2021, monthly DAA dispensing had not recovered to pre-pandemic levels. In contrast, ART and PrEP dispensing changed little over the same time period. Conclusions U.S. dispensing of DAAs to treat HCV fell at the start of the U.S. COVID-19 outbreak and has yet to fully recover to pre-pandemic levels. Addressing barriers to care is crucial to reach national HIV and hepatitis C elimination goals.

HIV and hepatitis C virus (HCV) impact millions of people and disproportionately burden socially marginalized groups. 1, 2 Left untreated, each can lead to advanced disease, worsened quality of life, and pre-mature death. Current U.S. and WHO initiatives call for the elimination of HIV and HCV by 2030. 3, 4 Life-saving pharmaceutical advancements in the past decadedirect-acting antivirals (DAAs) to cure HCV, antiretroviral treatment (ART) for HIV management, and pre-exposure prophylaxis (PrEP) for HIV prevention-have transformed these calls into tangible goals. 5 The coronavirus disease 2019 (COVID-19) pandemic likely impeded progress towards treating and eliminating HCV and HIV. Using data from a large clinical laboratory test provider with sites across the U.S., 1 study observed a 59% reduction in HCV antibody testing during April 2020. 6 Moreover, several reports document reduced HIV testing and delayed HIV care appointments following the initial outbreak. In a case study from New York, community-based organizations reported disruptions in all HIV care continuum services during April 2020, including testing, PrEP, and primary care. 7 Another case study from an academic medical center in Chicago documented a shift to telemedicine following "shelter in place" orders in late March 2020. During the next month, 45 of 98 scheduled HIV care visits were not attended nor were rescheduled. 8 These studies suggest that the outbreak was associated with fewer opportunities to diagnose HCV and HIV; however, they did not directly examine U.S. dispensing of DAAs, ART, and PrEP. Documenting national changes in dispensing of these drugs is essential to motivate action by clinicians and policymakers to ensure access to life-saving treatments for patients with HIV and HCV.

This study analyzed dispensing of DAAs, ART, and PrEP from May 2018 through April 2021 using a national dataset that reports 92% of U.S. prescriptions. To the authors' knowledge, this study provides the most complete and recent data on the national dispensing of these drugs.

In September 2021, the authors analyzed the IQVIA National Prescription Audit ® , which reports monthly dispensing counts from 92% of U.S. retail pharmacies and 70% of U.S. mail-order and long-term care pharmacies. 9 The study period encompassed 3 years of data, from May 2018 -April 2021. In the dataset, dispensing counts are projected to national totals using IQVIA's proprietary methodology. These counts are reported overall and according to patient age group, method of payment for prescriptions, and whether prescriptions are new prescriptions versus refills of a new prescription. In this context, "new" does not necessarily imply that the patient had no prior use of the drug; rather, it implies that the prescription was not a refill. The dataset lacks individual patient identifiers or information on prescription indication. Because data were de-identified, the Boston University IRB exempted this study from review.

DAAs were defined as products listed in Uniform System of Classification Level 5 category 82212 (Hepatitis C antivirals), excluding all ribavirin products. ART prescriptions were defined as products listed in Uniform System of Classification Level 3 category 82100 (HIV antivirals), excluding drugs defined as PrEP. PrEP prescriptions were defined as those for branded emtricitabine/tenofovir disproxil fumarate (Truvada®), which was approved for ART in 2004 and PrEP in 2012; 10 generic emtricitabine/tenofovir disproxil fumarate, which became available September 2020; 11 and branded emticitabine/tenofovir alafenamide (Descovy®), which was approved for ART in April 2016 and PrEP in October 2019. 12 Authors distinguished between these medications using variables for product name, combined molecule name, and branded versus generic status.

For each medication class, authors calculated the number of dispensed prescriptions per 100,000

Americans per month. Monthly population estimates were obtained from the U.S. Census Bureau. 13 Because monthly population estimates for 2021 were not available at the time of writing, the authors used linear regression to calculate the rate of change per month in population estimates between May 2018-December 2020, then extrapolated predictions to January-April 2021. Results were similar when subtracting the estimated number of COVID-19 decedents during January-April 2021 from projected population denominators.

To describe pre-pandemic dispensing of DAAs and ARTs, authors calculated the number of April 2020. Linear segmented regression models were used to assess immediate level and slope changes during April 2020, excluding data from this month as a washout period. Models used Newey-West robust SEs with a 1-month lag to account for first-order autocorrelation. In these models, the intercept is the predicted value of the outcome at baseline, the level change refers to any abrupt increase or decrease in the fitted line after the outbreak, and the slope change refers to any abrupt change in the slope of the fitted line after the outbreak compared with the preoutbreak slope.

In subgroup analyses, authors repeated segmented regression models by age group, method of payment, and delivery channel. Age group categories were 0-19 years, 20-39 years, 40-64 years, and >65 years. Authors used IQVIA's categorizations for payer type: (1) third-party (a category that mostly includes prescriptions paid via private insurance but also includes prescriptions paid by Medicaid managed care), (2) fee-for-service Medicaid, (3) Medicare, and (4) cash payment (i.e., self-pay). Delivery channel included (1) retail pharmacy (including chain pharmacies, food store pharmacies, and independent pharmacies), (2) mail-order pharmacy, and Table 1 Between October 2019 and February 2020, the monthly rate of PrEP dispensing did not change.

The outbreak was not associated with an immediate level or slope change in dispensing. Figure 2 displays trends in ART and PrEP dispensing. Table 2 shows coefficients from segmented regression models when stratifying by age group, payer type, and channel. For DAAs only, Table 2 also shows coefficients from when stratifying by whether prescriptions were new versus refills of prior prescriptions. Immediate level decreases occurred in April 2020 both for new and refill prescriptions, with modest upticks in the slopes. The immediate level decrease in DAA prescription dispensing was -0.52 prescriptions per 100,000 Americans (95% CI= -0.66, -0.38) for patients aged 20-39 years. Immediate level decreases also occurred for patients aged 40-64 years and aged ≥65 years. Unlike in patients aged 40-64 years and aged ≥65 years, there was no slope change in the months following the outbreak in DAA dispensing for patients aged 20-39 years. Level decreases in DAA prescription dispensing occurred for all methods of payment except cash payment, and also occurred for both the retail pharmacy and mail-order pharmacy channels.

As in the overall analysis of ART and PrEP dispensing, the outbreak was not associated with level changes for most subgroups. However, in contrast to the overall analysis, there was an immediate slope increase in dispensing of ARTs paid by Medicaid or by cash. Unlike other age groups, PrEP dispensing to patients aged 0-19 years was decreasing prior to April 2020 (-0.06 prescriptions per 100,000 patients per month, 95% CI= -0.08, -0.04). Following the outbreak, there was an abrupt level increase and a slope increase of 0.05 prescriptions per 100,000 patients per month, implying that the trend in PrEP dispensing in this age group was essentially flat after the outbreak.

The Appendix shows results of sensitivity analyses. Conclusions regarding ART dispensing were substantively unchanged when including the 3 PrEP drugs in the definition of ART, when defining the outbreak as March 2020 rather than April 2020, and when modeling total dispensed prescriptions.

This study is, to the authors' knowledge, the first to examine national dispensing of life-saving HCV and HIV drugs in the U.S. through the first year after the COVID-19 outbreak. 14 We find that the COVID-19 outbreak in April 2020 was associated with a sharp decrease in DAA prescription dispensing and that levels of dispensing remained below their pre-pandemic baseline in April 2021. In contrast, the outbreak was associated with minimal changes in dispensing of ART or PrEP drugs.

The study's findings on DAA dispensing are consistent with a prior Canadian analysis of drugs reimbursed by the Ontario Drug Benefit. That analysis observed a sharp decline (49.3%) in the number of DAA prescriptions dispensed in the quarter following the introduction of COVID-19

restrictions. The current study builds upon the Canadian analysis by using U.S. data and examining dispensing patterns over a longer period.

The study's findings raise concerns that the pandemic has substantially disrupted efforts to eliminate HCV using DAAs. One explanation for decreased DAA dispensing in this study may be that fewer patients were newly diagnosed with HCV, a possibility supported by a prior study showing that HCV testing decreased following the COVID-19 outbreak. 6 Another explanation is that patients with HCV already connected to care received DAA treatment before April 2020, meaning that patients eligible for treatment during the pandemic were those with poor care access. Detecting HCV in these hard-to-reach patients and initiating treatment may have been particularly difficult following the COVID-19 outbreak.

In subgroup analyses, there were large decreases in DAA dispensing in patients aged [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] years. This is a particularly important group from the perspective of public health, as it disproportionately accounts for people who inject drugs and have HCV, a highly marginalized population with substantial barriers to care. 15 Additionally, this study found that dispensing of both new and refill prescriptions for DAAs decreased following the outbreak. This finding raises the possibility that both initiation and completion of DAA therapy were disrupted by the pandemic. Notably, because the study dataset does not report days supplied of prescriptions, it could not be determined whether the decrease in DAA refills reflected a shift towards the provision of larger new prescriptions, obviating the need for refills. Future research should assess the reasons for observed decreases in new and refill DAA prescriptions, using datasets with individual patient identifiers and prescription duration.

Due to cost and prior authorization requirements, many DAA prescriptions are filled through specialty pharmacies which route through mail order channels. This study found that DAA dispensing for both retail and mail-order channels dropped substantially in April 2020. The drop in mail-order dispensing occurred even though social distancing measures would not have impeded dispensing through this channel, unlike dispensing in retail pharmacies. This finding is consistent with potentially decreased demand for DAAs, perhaps owing to disruptions in healthcare visits and HCV screening.

The study's findings on DAA dispensing have important implications for policy makers and clinicians, as they suggest that the pandemic has further disrupted a hepatitis C treatment system that was already challenged by poor patient access, high treatment costs, and inadequate provider capacity. 1,2 Other work has suggested COVID-19 exacerbated existing U.S. disparities, with disproportionately negative health consequences for socially marginalized groups. 16 Despite early reports fearing disruption to HIV treatment services, 7,8 ART dispensing did not change substantially after the COVID-19 outbreak. The authors speculate that a potential reason is the unprecedented shift towards delivering care for chronic diseases using telehealth during the pandemic. 18 Notably, patients living with HIV who receive ART include those who know their status and have consistent access to care. In 2019, an estimated 13% of Americans living with HIV did not know they have the virus; moreover, of all patients diagnosed with HIV in 2019, 24% did not receive any HIV medical care. 19 Thus, while the apparent lack of decrease in dispensing of ART is reassuring, gaps in identifying patients with undiagnosed HIV and initiating ART in these patients remain.

PrEP dispensing did not change substantially after the outbreak overall and for most age groups. This is potentially surprising given that other studies of PrEP use during the pandemic have shown decreased use. 20 Small studies with self-reported data conducted outside the U.S. One potential explanation for the discrepancy is the use of national medication dispensing data from the U.S. Another potential explanation is mismeasurement of PrEP dispensing. This analysis assumed that all use of the 3 PrEP drugs were for PrEP as opposed to ART. If it could have differentiated between dispensing of these drugs by indication, it is possible that it would have similarly found decreased PrEP use. Future studies should assess PrEP use during the pandemic using data sources that have information on indication, such as insurance claims and electronic health records. If PrEP dispensing was indeed stable during the pandemic, studies should explore why use did not decrease. Possibilities include the local rollout of the federal program Ready, Set, PrEP starting in December 2019, 23 the introduction of generic PrEP in September 2020, 11 and the growing availability of online prescribing and dispensing of PrEP. 24 The one age group for which PrEP dispensing changed was patients aged 0-19 years. In this age group, the pre-existing decline in the rate of dispensing attenuated after the COVID-19 outbreak, resulting in an essentially flat trend. While the reasons for these findings are unclear, this is of clinical and public policy concern in light of evidence suggesting underuse of PrEP in adolescents with the greatest risk for HIV. 25 The authors' ability to capture recent national data on dispensing of DAAs, ART and PrEP stands in stark contrast to the 2 year-lag for national statistics reporting the incidence, prevalence, and treated prevalence for HIV and HCV. Data on disease incidence and prevalence are critical aspects of efforts to reduce and even eliminate HCV and HIV. Policymakers should invest the resources needed to obtain these data in a timelier fashion. The authors join Barocas et al. call for recommitting resources to screen, link, and treat people with HCV 26 and HIV.

This study has limitations. First, the dataset lacked clinical details, individual patient identifiers, or information on prescription indication. Consequently, it could not be determined whether declines in dispensing particularly affected vulnerable patient populations, such as people who inject drugs, or identify the precise reason for changes in dispensing patterns. Second, the method for counting PrEP prescriptions is imprecise and consequently, estimates of levels and changes in PrEP use may be prone to errors. Third, the dataset does not include information on individuals who are not receiving treatment for HIV or HCV. This is particularly relevant for this study's findings on HIV medications, as many Americans who should be taking these medications are not doing so. Fourth, authors could not assess changes in dispensing by geographic units such as states.

Following the U.S. outbreak of COVID-19, dispensing of DAAs to treat HCV fell sharply and has yet to fully recover to pre-pandemic levels. Dispensing of ART to treat HIV and PrEP to prevent HIV remained stable. Future work should monitor changes in dispensing of the study drugs, assess reasons for treatment declines if detected, and identify evidence-based solutions to overcome barriers to disease detection and treatment.

The research presented in this paper is that of the authors and does not reflect the official policy of the NIH.

Access to IQVIA data was provided through the IQVIA Institute's Human Data Science

Research Collaborative, the purpose of which is to promote research into the effects of the COVID-19 pandemic on the U.S. health care system. The data provider had no role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. The study sponsors had no role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. No other financial disclosures were reported by the authors of this paper. Boldface indicates statistical significance(*p<0.05; **p<0.01; ***p<0.001). All coefficients for intercept also significant at ***p<0.001. Interpretation: the intercept, is the estimated baseline level of the outcome variable; "change per month before April 2020" is the slope, or trajectory of the outcome (dispensed prescriptions per 100,000 Americans) until the start of the U.S. COVID-19 outbreak; "level change during April 2020" represents the change in the level of the outcome that occurs in the period immediately following the outbreak ; "slope change after April 2020"represents the immediate change in slope that occurs after the outbreak compared with the pre-outbreak slope. 0.00 (-0.03, 0.03) Notes: Boldface indicates statistical significance (*p<0.05; **p<0.01; ***p<0.001). All coefficients for intercept also significant at ***p<0.001. Interpretation: the intercept, is the estimated baseline level of the outcome variable; "change per month before April 2020" is the slope, or trajectory of the outcome (dispensed prescriptions per 100,000 Americans) until the start of the U.S. COVID-19 outbreak; "level change during April 2020" represents the change in the level of the outcome that occurs in the period immediately following the outbreak ; "slope change after April 2020"represents the immediate change in slope that occurs after the outbreak compared with the pre-outbreak slope. a Results for a small number of prescriptions with unknown age are not displayed. Data source: IQVIA National Prescription Audit ® ; timeframe: May 2018-April 2021. DAAs were defined as products listed in Uniform System of Classification Level 5 category 82212 (hepatitis C antivirals), excluding all ribavirin products. ART were defined as products listed in

Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report 2019 -Hepatitis C. U.S. Department of Health & Human Services

Department of Health and Human Services

World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva: World Health Organization

The science is clear: with HIV

Department of Health and Human Services

Decreases in hepatitis C testing and treatment during the COVID-19 pandemic

COVID-19 pandemic disrupts HIV continuum of care and prevention: implications for research and practice concerning community-based organizations and frontline providers

HIV care continuum and COVID-19 outcomes among people living with HIV during the COVID-19 pandemic

FDA In Brief: FDA continues to encourage ongoing education about the benefits and risks associated with PrEP, including additional steps to help reduce the risk of getting HIV

Food & Drug Administration

Form 10-Q: Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

Monthly Population Estimates for the United States

Impact of COVID-19 on prescribing trends of direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada

Hepatitis C transmission in young people who inject drugs: insights using a dynamic model informed by state public health surveillance

Racial and ethnic health disparities related to COVID-19

Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment

The impact of COVID-19 on HIV care provided via telemedicine-past, present, and future

Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 dependent areas

Changes in sexual behavior, PrEP adherence, and access to sexual health services due to the COVID-19 pandemic among a cohort of PrEP-using MSM in the South

Substantial decline in use of HIV preexposure prophylaxis following introduction of COVID-19 physical distancing restrictions in Australia: results from a prospective observational study of gay and bisexual men

Public health morality, sex, and COVID-19: sexual minority men's HIV pre-exposure prophylaxis (PrEP) decision-making during Ontario's first COVID-19 lockdown

Office of Infectious Disease and HIV/AIDS Policy. Ready, Set, PrEP Expands Access to HIV Prevention Medications

Online Ways to Get PrEP

HIV preexposure prophylaxis among adolescents in the US: a review

Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study

Uniform System of Classification Level 3 category 82100 (HIV antivirals), excluding the 3 PrEP drugs, which were defined as Descovy®, Truvada®, and generic combination emtricitabine/tenofovir disproxil fumarate

Andrew Aronsohn: Conceptualization, Methodology, Writing -Review & Editing. Kao-Ping Chua: Conceptualization, Methodology, Software, Formal analysis, Data Curation, Writing -Review & Editing, Supervision. Rena Conti Conceptualization